Clinical approaches to immunotherapy in non-small cell lung cancer: Current and future perspectives

Shawn J. Rice, Bruce Miller, Matthias Wagman, Daniel S. Jamorabo, Xin Liu, Chandra P. Belani

Research output: Contribution to journalReview article

Abstract

Lung cancer is among the most prevalent and deadly cancers. Although the development of targeted drugs, erlotinib and crizotinib, has improved lung cancer management, survival rates of lung cancer patients have not shown significant improvement over the past decade. Better therapeutic options are required to treat lung cancer patients. Immunotherapy is a maturing and rapidly growing field, which has recently contributed many novel strategies for addressing cancer treatment. Here, we discuss the current state of cancer vaccines, immune checkpoint blockers, and adoptive cellular therapies, as novel clinical treatment strategies for non-small cell lung cancer. The durability of clinical activity in a subset of patients has led to a great deal of excitement and optimism.

Original languageEnglish (US)
Pages (from-to)183-195
Number of pages13
JournalCurrent Molecular Pharmacology
Volume9
Issue number3
DOIs
StatePublished - Aug 1 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Immunotherapy
Lung Neoplasms
Cancer Vaccines
Therapeutics
Neoplasms
Survival Rate
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Rice, Shawn J. ; Miller, Bruce ; Wagman, Matthias ; Jamorabo, Daniel S. ; Liu, Xin ; Belani, Chandra P. / Clinical approaches to immunotherapy in non-small cell lung cancer : Current and future perspectives. In: Current Molecular Pharmacology. 2016 ; Vol. 9, No. 3. pp. 183-195.
@article{b951fa3ee96d409a82394a05add7e3c5,
title = "Clinical approaches to immunotherapy in non-small cell lung cancer: Current and future perspectives",
abstract = "Lung cancer is among the most prevalent and deadly cancers. Although the development of targeted drugs, erlotinib and crizotinib, has improved lung cancer management, survival rates of lung cancer patients have not shown significant improvement over the past decade. Better therapeutic options are required to treat lung cancer patients. Immunotherapy is a maturing and rapidly growing field, which has recently contributed many novel strategies for addressing cancer treatment. Here, we discuss the current state of cancer vaccines, immune checkpoint blockers, and adoptive cellular therapies, as novel clinical treatment strategies for non-small cell lung cancer. The durability of clinical activity in a subset of patients has led to a great deal of excitement and optimism.",
author = "Rice, {Shawn J.} and Bruce Miller and Matthias Wagman and Jamorabo, {Daniel S.} and Xin Liu and Belani, {Chandra P.}",
year = "2016",
month = "8",
day = "1",
doi = "10.2174/1874467208666150716120108",
language = "English (US)",
volume = "9",
pages = "183--195",
journal = "Current Molecular Pharmacology",
issn = "1874-4702",
publisher = "Bentham Science Publishers",
number = "3",

}

Clinical approaches to immunotherapy in non-small cell lung cancer : Current and future perspectives. / Rice, Shawn J.; Miller, Bruce; Wagman, Matthias; Jamorabo, Daniel S.; Liu, Xin; Belani, Chandra P.

In: Current Molecular Pharmacology, Vol. 9, No. 3, 01.08.2016, p. 183-195.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Clinical approaches to immunotherapy in non-small cell lung cancer

T2 - Current and future perspectives

AU - Rice, Shawn J.

AU - Miller, Bruce

AU - Wagman, Matthias

AU - Jamorabo, Daniel S.

AU - Liu, Xin

AU - Belani, Chandra P.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Lung cancer is among the most prevalent and deadly cancers. Although the development of targeted drugs, erlotinib and crizotinib, has improved lung cancer management, survival rates of lung cancer patients have not shown significant improvement over the past decade. Better therapeutic options are required to treat lung cancer patients. Immunotherapy is a maturing and rapidly growing field, which has recently contributed many novel strategies for addressing cancer treatment. Here, we discuss the current state of cancer vaccines, immune checkpoint blockers, and adoptive cellular therapies, as novel clinical treatment strategies for non-small cell lung cancer. The durability of clinical activity in a subset of patients has led to a great deal of excitement and optimism.

AB - Lung cancer is among the most prevalent and deadly cancers. Although the development of targeted drugs, erlotinib and crizotinib, has improved lung cancer management, survival rates of lung cancer patients have not shown significant improvement over the past decade. Better therapeutic options are required to treat lung cancer patients. Immunotherapy is a maturing and rapidly growing field, which has recently contributed many novel strategies for addressing cancer treatment. Here, we discuss the current state of cancer vaccines, immune checkpoint blockers, and adoptive cellular therapies, as novel clinical treatment strategies for non-small cell lung cancer. The durability of clinical activity in a subset of patients has led to a great deal of excitement and optimism.

UR - http://www.scopus.com/inward/record.url?scp=84989244231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989244231&partnerID=8YFLogxK

U2 - 10.2174/1874467208666150716120108

DO - 10.2174/1874467208666150716120108

M3 - Review article

C2 - 26177648

AN - SCOPUS:84989244231

VL - 9

SP - 183

EP - 195

JO - Current Molecular Pharmacology

JF - Current Molecular Pharmacology

SN - 1874-4702

IS - 3

ER -